More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Growth in Eliquis drug also led to an upside in the top line. Consequently, the company raised its annual earnings guidance. Following this, the stock also rallied. BMY is banking on newer drugs ...

If you have trouble affording prescription drugs, some independent pharmacists say that so-called pharmacy middlemen are ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand ...

Following Keytruda, Bristol-Myers Squibb (BMS) and Pfizer's Eliquis (apixaban), an oral anticoagulant, will be the second best-selling drug out of the top ten, with annual sales of $18.7 billion ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...

My daughter’s annual pharmacy bill is routinely a multiple of my salary as a state employee whose family relies on the health ...